Australia's most trusted
source of pharma news
Thursday, 20 March 2025
Posted 17 March 2025 PM
In a stroke of extraordinary good luck, BioNTech CEO, Ugur Sahin, collected close to half a billion dollars in 2024, the reward of a large share option deal signed three months before a monster windfall for the company.
The option was awarded in September 2019 before anyone had heard of COVID-19 and three months before the virus would emerge in China and six months before the World Health Organisation declared a pandemic.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.